In the past decade, an increasing number of clinical trials are reporting evidence that psychedelics or serotonergic hallucinogens (such as lysergic acid diethylamide, psilocybin, and ayahuasca/dimethyltryptamine) could be effective in the treatment of mood, anxiety, and substance use disorders. The mechanisms responsible for these effects are not fully understood but seem to involve changes in bran dynamics in areas rich in serotonergic 5-HT receptors and in personality. In the present text, we present a brief and critical overview of the current research in this field, pointing out both promises and limitations of these studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acschemneuro.8b00237 | DOI Listing |
Toxicol Rep
June 2025
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal.
Drug use represents a prevalent and multifaceted societal problem, with profound implications for public health, social welfare, and economic stability. To circumvent strict international drug control regulations, there is a growing trend in the development and market introduction of novel psychoactive substances (NPS), encompassing a wide range of compounds with psychoactive properties. This includes, among other classes of drugs, the phenethylamines.
View Article and Find Full Text PDFConscious Cogn
January 2025
Humane Technology Lab, Catholic University of Sacred Heart, Milan, Italy; Applied Technology for Neuro-Psychology Lab., Istituto Auxologico Italiano IRCCS, Milan, Italy. Electronic address:
Psychedelic drugs offer valuable insights into consciousness, but disentangling their causal effects on perceptual and high-level cognition is nontrivial. Technological advances in virtual reality (VR) and machine learning have enabled the immersive simulation of visual hallucinations. However, comprehensive experimental data on how these simulated hallucinations affects high-level human cognition is lacking.
View Article and Find Full Text PDFJ Cannabis Res
January 2025
Anesthesiology Department, University of Michigan Medical School, Ann Arbor, MI, 48105, USA.
Introduction: Chronic pain is common among Veterans, some of whom use cannabis for pain. We conducted a feasibility pilot study of a novel coaching intervention to help Veterans optimize use of medical cannabis products for pain management (NCT06320470).
Methods: The intervention drew from scientific literature, consultation with cannabis experts, Veteran input via a Community Advisory Board, and tenets of motivational interviewing.
JAMA Netw Open
January 2025
Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego.
Importance: The degree that in-home cannabis smoking can be detected in the urine of resident children is unclear.
Objective: Test association of in-home cannabis smoking with urinary cannabinoids in children living at home.
Design, Setting, And Participants: This cross-sectional study used baseline data from Project Fresh Air, a 2012-2016 randomized clinical trial to reduce fine particulate matter levels.
Palliat Support Care
January 2025
Assistant Attending Behavioral Scientist, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: The recent wave of clinical trials of psychedelic substances among patients with life-limiting illness has largely focused on individual healing. This most often translates to a single patient receiving an intervention with researchers guiding them. As social isolation and lack of connection are major drivers of current mental health crises and group work is expected to be an important aspect of psychedelic assisted psychotherapy, it is essential that we understand the role of community in psychedelic healing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!